Germany / STADA’s Bold Bets on M&A
After a year of growth and acquisitions, 125-year-old German generics manufacturer STADA is showing a willingness to make bold bets on areas including consumer healthcare, medical cannabis, and research into…
Address: Werner-von-Siemens-Straße 22-28
64625 Bensheim
Tel: +49 (0) 6251 – 1083-0
Web: http://www.koehler-chemie.de/deutsch/startseite/
Dr. Franz Köhler Chemie, the company, specialises in organ-protecting solutions, therapeutics, x-ray contrast agents and antidotes. On this basis, Dr. Gernot Köhler, from the second generation, has expanded the company into an innovative, research-intensive and high performance pharmaceuticals company in Alsbach, the USA and Russia. Distributing associates represent the company worldwide. Internal research makes innovative products and continuous development possible. As a result, new therapeutic approaches are formulated in close co-operation with qualified doctors and research is carried out effectively and dependent on requirements. “We are at your service” is the mission statement with which we shall continue to contribute to advances in science and medicine in the interests of the user and patients alike.
Dr. Franz Josef Köhler founded the company in 1959. He is the founder of aspartic therapy and a promoter of organ-protecting solutions. In his honour, the German Society for Thoracic and Cardiovascular Surgery has awarded the “Franz J. Köhler Award” every year since 1990, for outstanding work in the field of organ protection with special emphasis on the heart. His son, Dr. Gernot Köhler, has headed this modern medium sized company since 1984, guiding it into new areas of business.
Dr. Franz Köhler Chemie produces at two German locations thereby meeting the increasing international demand for organ-protecting solutions. The products, perfusion, infusion and injection solutions from Alsbach and Bensheim in South Hesse are in a leading position internationally.
After a year of growth and acquisitions, 125-year-old German generics manufacturer STADA is showing a willingness to make bold bets on areas including consumer healthcare, medical cannabis, and research into…
German biotech BioNTech has been thrust into the global spotlight thanks to its collaboration with global giant Pfizer on a COVID-19 vaccine. The company, founded by Professor Ugur Sahin in…
PharmaBoardroom recently sat down with Merck’s EVP and Head of Global Healthcare Operations, Teresa Rodó to unpack her important role within the global group and how Merck has pivoted to…
Merck KGaA has moved to continuously expand its manufacturing capacity and capability in recent years with a number of headline-grabbing investments in sites in its home market of Germany and…
Emmanuel Macron and Angela Merkel recently put their heads together to come up with a health strategy that would ensure greater European access to innovative medicines and COVID-19 treatments. …
Some of the top recent stories from Germany, Europe’s leading pharma market according to CPhI, including big new investments from Merck and Bayer, the implications of the country’s new Digital…
Bayer’s latest move to buy out BlueRock Therapeutics comes with a price tag of USD 600 million in total as the company increasingly looks toward cell and gene therapies to…
German giant Merck KGaA has announced a EUR one billion investment into its headquarters in Darmstadt, Germany up until 2025. The aim of Merck’s proposed investment is to secure…
As a majority family owned group, Merck is also the oldest pharmaceutical company in the world and known throughout the market for its long-term vision. How would you compare this…
The 2006 acquisition of Schering by Bayer is a prime example of the way that big pharma is now approaching growth through acquisition in this extremely competitive and challenging global…
DAIICHI SANKYO in Germany, Austria and Switzerland DAIICHI SANKYO wants to be a Global Pharma Innovator with Germany at the center of this process on the European continent. An example…
Many companies that are focused in the diabetes segment have recognised the need to strengthen their operations in emerging markets, due to the increased prevalence of the disease in countries…
See our Cookie Privacy Policy Here